Darigabat is a Small Molecule owned by Cerevel Therapeutics Holdings, and is involved in 12 clinical trials, of which 9 were completed, 2 are ongoing, and 1 is planned.

CVL-865 (PF-06372865) is a subtype-selective positive allosteric modulator at GABAA receptors. The drug candidate binds primarily to the alpha 2/3/5 subtypes which are responsible for the anti-anxiety effects of these kind of drugs, but has relatively little efficacy at the alpha1 subtype which produces the sedative and memory loss effects. Therefore the drug candidate allosterically modulates the effects of GABAA and controls the symptoms associated with the disease.

The revenue for Darigabat is expected to reach a total of $1.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Darigabat NPV Report.

Darigabat was originated by Pfizer and is currently owned by Cerevel Therapeutics Holdings.

Darigabat Overview

Darigabat (CVL-865) is under development for the treatment of  panic disorder and drug-resistant focal onset seizures. It is administered orally as a tablet. The drug candidate specifically targets alpha 2,3 and 5 subunits of GABA-A receptor to overcome the significant side effects associated with alpha 1 binding. It was under development for the treatment for chronic low back pain and generalized anxiety disorder.

Cerevel Therapeutics Holdings Overview

Cerevel Therapeutics Holdings (Cerevel Therapeutics) is a biopharmaceutical company. It develops and commercializes medicines for the treatment of central nervous system (CNS) disorders. Cerevel Therapeutics is headquartered in Boston, Massachusetts, United States.

The operating loss of the company was US$220.1 million in FY2021, compared to an operating loss of US$149.1 million in FY2020. The net loss of the company was US$225.3 million in FY2021, compared to a net loss of US$152.1 million in FY2020.

Quick View – Darigabat

Report Segments
  • Innovator
Drug Name
  • Darigabat
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.